These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 8163420)

  • 1. Diagnostic testing for pituitary pars intermedia dysfunction in horses.
    Dybdal NO; Hargreaves KM; Madigan JE; Gribble DH; Kennedy PC; Stabenfeldt GH
    J Am Vet Med Assoc; 1994 Feb; 204(4):627-32. PubMed ID: 8163420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma.
    Eiler H; Oliver JW; Andrews FM; Fecteau KA; Green EM; McCracken M
    J Am Vet Med Assoc; 1997 Jul; 211(1):79-81. PubMed ID: 9215417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
    Lee ZY; Zylstra R; Haritou SJ
    Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
    Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
    Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
    McFarlane D; Cribb AE
    Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agreement in histologic assessments of the pituitary pars intermedia in aged horses.
    McFarlane D; Miller LM; Craig LE; Dybdal NO; Habecker PL; Miller MA; Patterson JS; Cribb AE
    Am J Vet Res; 2005 Dec; 66(12):2055-9. PubMed ID: 16379646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian and circannual rhythms of cortisol, ACTH, and α-melanocyte-stimulating hormone in healthy horses.
    Cordero M; Brorsen BW; McFarlane D
    Domest Anim Endocrinol; 2012 Nov; 43(4):317-24. PubMed ID: 22717182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction.
    Beech J; Boston RC; McFarlane D; Lindborg S
    J Am Vet Med Assoc; 2009 Sep; 235(6):715-22. PubMed ID: 19751169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Melanocyte--stimulating hormone and adrenocorticotropin concentrations in response to thyrotropin-releasing hormone and comparison with adrenocorticotropin concentration after domperidone administration in healthy horses and horses with pituitary pars intermedia dysfunction.
    Beech J; McFarlane D; Lindborg S; Sojka JE; Boston RC
    J Am Vet Med Assoc; 2011 May; 238(10):1305-15. PubMed ID: 21568777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
    Beech J; Boston R; Lindborg S
    J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI; Litchfield E; Heller J; Hughes KJ
    Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.
    McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE
    J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a six-hour combined dexamethasone suppression/ACTH stimulation test in dogs with hyperadrenocorticism.
    Feldman EC
    J Am Vet Med Assoc; 1986 Dec; 189(12):1562-6. PubMed ID: 3025143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of results of adrenocorticotropic hormone stimulation and low-dose dexamethasone suppression tests with necropsy findings in dogs: 81 cases (1985-1995).
    Van Liew CH; Greco DS; Salman MD
    J Am Vet Med Assoc; 1997 Aug; 211(3):322-5. PubMed ID: 9262671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equine pituitary pars intermedia dysfunction.
    McFarlane D
    Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
    Copas VE; Durham AE
    Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined dexamethasone suppression and cosyntropin (synthetic ACTH) stimulation test in the dog: new approach to testing of adrenal gland function.
    Eiler H; Oliver J
    Am J Vet Res; 1980 Aug; 41(8):1243-6. PubMed ID: 6255830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.